Henagliflozin: all 27 studies that test it
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEFNot yet recruitingNCT07687212Phase 1/2
- Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMRNot yet recruitingNCT07294495Not applicable
- Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）Not yet recruitingNCT07027774Phase 4
- The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin TherapyRecruitingNCT06818851Phase 4
- Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DMNot yet recruitingNCT06762223Phase 4
- Henagliflozin's Impact on Prediabetes RemissionNot yet recruitingNCT06448130Phase 4
- Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver DiseaseNot yet recruitingNCT06218342Phase 4
- Efficacy of Henagliflozin for Weight Loss in Obesity Without DiabetesNot yet recruitingNCT06216340Phase 4
- The Effect of Henagliflozin and Metformin on Myocardial Tissue-level CharacteristicsNot yet recruitingNCT06059287Not applicable
- Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal AxisNot yet recruitingNCT06031389Not applicable
- Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)RecruitingNCT05742230Not applicable
- Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial InfarctionCompletedNCT06187727Phase 4
- Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical TrialCompletedNCT06085703Not applicable
- Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DMCompletedNCT05677334Phase 4
- Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 DiabetesStatus unknownNCT04390295Phase 3
- Drug-drug Interaction Between Simvastatin and SHR3824Status unknownNCT03329118Phase 1
- Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic ImpairmentStatus unknownNCT03160014Phase 1
- Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal InsufficientStatus unknownNCT03159832Phase 1
- Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 DiabetesStatus unknownNCT03159052Phase 3
- The Drug-drug Interaction of SHR3824 and SP2086Status unknownNCT02500485Phase 1
- The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366377Phase 1
- The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus PatientsStatus unknownNCT02366351Phase 1
- The PK/PD Study of Multiple Dose of SHR3824 in Healthy VolunteersCompletedNCT02361138Phase 1
- The PK/PD Study of Single Dose of SHR3824 in Healthy VolunteersCompletedNCT02356224Phase 1
- The Drug-drug Interaction of SHR3824 and MetforminCompletedNCT02354027Phase 1
- Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy SubjectsCompletedNCT02353975Phase 1
- Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus PatientsCompletedNCT02346175Phase 1